AIMS/HYPOTHESIS: Five insulin analogues, with modified insulin-like molecular structures, are currently approved for treating diabetic patients. They activate cell signalling and biological responses via insulin receptor isoforms (IR-A and IR-B), each having specific characteristics for eliciting cell responses. The molecular and biological effects of these analogues on receptor isoforms in comparison to native insulin are not well defined, and their effects on the IGF1 receptor (IGF1R) are controversial. The characterisation of these effects was the aim of the present study. METHODS: Short-acting (insulin lispro [B28Lys,B29Pro human insulin], insulin aspart [B28Asp human insulin], insulin glulisine [B3Lys,B29Glu human insulin]) and long-acting (insulin glargine [A21Gly,B31Arg,B32Arg human insulin], insulin detemir [B29Lys(epsilon-tetradecanoyl),desB30 human insulin]) insulin analogues were studied in three engineered cell models (R(-), IGF1R-deprived mouse fibroblasts transfected with either only human IR-A or IR-B or IGF1R). Receptor binding and phosphorylation, AKT and extracellular signal-regulated kinase (ERK) activation, cell proliferation and colony formation were evaluated after exposing the cells to each analogue and were compared with insulin, IGF1 and the carcinogenic analogue B10Asp. RESULTS: All short-acting insulin analogues produced molecular and biological effects similar but not identical to those of insulin. Relative to insulin, long-acting analogues more strongly activated the ERK pathway via both IR-A and IGF1R as well as increased cell proliferation. At the concentration tested, no analogue (except B10Asp via IR-A) had increased transforming activity. CONCLUSIONS/ INTERPRETATION: Cell models that permit comparisons of the activity of insulin to that of insulin analogues via each receptor individually indicate that only minor differences exist between insulin and short-acting analogues. By contrast, long-acting analogues activate the mitogenic signalling pathway more effectively than insulin and cause increased cell proliferation.
AIMS/HYPOTHESIS: Five insulin analogues, with modified insulin-like molecular structures, are currently approved for treating diabeticpatients. They activate cell signalling and biological responses via insulin receptor isoforms (IR-A and IR-B), each having specific characteristics for eliciting cell responses. The molecular and biological effects of these analogues on receptor isoforms in comparison to native insulin are not well defined, and their effects on the IGF1 receptor (IGF1R) are controversial. The characterisation of these effects was the aim of the present study. METHODS: Short-acting (insulin lispro [B28Lys,B29Pro humaninsulin], insulin aspart [B28Asp humaninsulin], insulin glulisine [B3Lys,B29Glu humaninsulin]) and long-acting (insulin glargine [A21Gly,B31Arg,B32Arg humaninsulin], insulin detemir [B29Lys(epsilon-tetradecanoyl),desB30 humaninsulin]) insulin analogues were studied in three engineered cell models (R(-), IGF1R-deprived mouse fibroblasts transfected with either only human IR-A or IR-B or IGF1R). Receptor binding and phosphorylation, AKT and extracellular signal-regulated kinase (ERK) activation, cell proliferation and colony formation were evaluated after exposing the cells to each analogue and were compared with insulin, IGF1 and the carcinogenic analogue B10Asp. RESULTS: All short-acting insulin analogues produced molecular and biological effects similar but not identical to those of insulin. Relative to insulin, long-acting analogues more strongly activated the ERK pathway via both IR-A and IGF1R as well as increased cell proliferation. At the concentration tested, no analogue (except B10Asp via IR-A) had increased transforming activity. CONCLUSIONS/ INTERPRETATION: Cell models that permit comparisons of the activity of insulin to that of insulin analogues via each receptor individually indicate that only minor differences exist between insulin and short-acting analogues. By contrast, long-acting analogues activate the mitogenic signalling pathway more effectively than insulin and cause increased cell proliferation.
Authors: F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri Journal: Mol Cell Biol Date: 1999-05 Impact factor: 4.272
Authors: L J Slieker; G S Brooke; R D DiMarchi; D B Flora; L K Green; J A Hoffmann; H B Long; L Fan; J E Shields; K L Sundell; P L Surface; R E Chance Journal: Diabetologia Date: 1997-07 Impact factor: 10.122
Authors: K Staiger; H Staiger; M A Schweitzer; E Metzinger; B Balletshofer; H-U Häring; M Kellerer Journal: Diabetologia Date: 2005-08-03 Impact factor: 10.122
Authors: Artur Matyszewski; Anna Czarnecka; Maciej Kawecki; Piotr Korzeń; Ilan J Safir; Wojciech Kukwa; Cezary Szczylik Journal: Oncol Lett Date: 2015-06-04 Impact factor: 2.967
Authors: Igor Pomytkin; João P Costa-Nunes; Vladimir Kasatkin; Ekaterina Veniaminova; Anna Demchenko; Alexey Lyundup; Klaus-Peter Lesch; Eugene D Ponomarev; Tatyana Strekalova Journal: CNS Neurosci Ther Date: 2018-04-24 Impact factor: 5.243
Authors: Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri Journal: Endocr Rev Date: 2017-10-01 Impact factor: 19.871